Cowen analyst Charles Ryhee raised the firm’s price target on Evolent Health (EVH) to $59 from $57 and keeps an Outperform rating on the shares. The analyst updated the firm’s to incorporate the recently announced Humana (HUM) contract win and the closing of its NIA acquisition which closed 2 months earlier than our model previously assumed. The Hjumana contract which goes live 2H23, is expected to bring $250M in annualized revenue.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EVH:
- Centene completes divestiture of Magellan Specialty Health to Evolent Health
- Evolent Health jumps after announcing expansion of Humana pact
- Evolent Health price target raised to $51 from $44 at Piper Sandler
- Evolent Health management to meet with BTIG
- Evolent Health price target raised to $44 from $33 at Piper Sandler